The estimated Net Worth of Neil A Klompas is at least $832 mil dollars as of 10 March 2023. Mr Klompas owns over 5,208 units of Zymeworks BC Inc stock worth over $242,109 and over the last 6 years he sold ZYME stock worth over $0. In addition, he makes $589,864 as Exec. VP of Bus. Operations & CFO at Zymeworks BC Inc.
Mr has made over 5 trades of the Zymeworks BC Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 5,208 units of ZYME stock worth $63,017 on 10 March 2023.
The largest trade he's ever made was exercising 25,000 units of Zymeworks BC Inc stock on 9 December 2020 worth over $129,500. On average, Mr trades about 3,313 units every 88 days since 2019. As of 10 March 2023 he still owns at least 20,009 units of Zymeworks BC Inc stock.
You can see the complete history of Mr Klompas stock trades at the bottom of the page.
Neil A. Klompas C.A., CPA, CPA, CA is the Exec. VP of Bus. Operations & CFO at Zymeworks BC Inc.
As the Exec. VP of Bus. Operations & CFO of Zymeworks BC Inc, the total compensation of Mr CA at Zymeworks BC Inc is $589,864. There are 2 executives at Zymeworks BC Inc getting paid more, with Dr. Ali Tehrani having the highest compensation of $877,656.
Mr CA is 49, he's been the Exec. VP of Bus. Operations & CFO of Zymeworks BC Inc since . There are 5 older and no younger executives at Zymeworks BC Inc. The oldest executive at Zymeworks BC Inc is Dr. Jennifer Kaufman-Shaw L.L.B., LLB, Ph.D., 71, who is the VP of Intellectual Property.
Neil's mailing address filed with the SEC is C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709.
Over the last 6 years, insiders at Zymeworks BC Inc have traded over $15,586,802 worth of Zymeworks BC Inc stock and bought 5,881,975 units worth $49,789,204 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Capital, Llc Eco R1, eGroup, Llc Green Jeremy Red.... On average, Zymeworks BC Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,629,555. The most recent stock trade was executed by Kenneth Galbraith on 5 January 2024, trading 47,666 units of ZYME stock currently worth $576,759.
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.
Zymeworks BC Inc executives and other stock owners filed with the SEC include: